Mobile App

Google Play Apple Store
Quarterly Brief (January-March, 2022): A Current Expert Analysis on Important HIV Clinical Decisions
AMA/ANCC/ACPE Activities

New frontiers for HIV therapy continue to be explored, as underscored by the clinical development and use of new agents, changing regimen strategies and development of long-acting novel agents. This expanding era of simplified and effective HIV therapy presents physicians with many new opportunities and challenges for providing care. To deliver state-of-the-art HIV prevention and care, healthcare providers must stay informed regularly of new clinical data and treatment recommendations in HIV.

This educational Quarterly Brief, covering HIV data from January through March of 2022 will discuss the most clinically relevant information regarding PrEP, HIV cure, treatment experienced patients, long-acting ART and comorbidities.

Review the Full Program or segment of interest. Claim up to 0.5 AMA, ANCC, or ACPE credit/contact hour(s) after completion of a brief post-test/evaluation.









Faculty Chair
Paul Sax, MD Paul Sax, MD
Clinical Director
Division of Infectious Diseases
Brigham and Women’s Hospital
Professor of Medicine
Harvard Medical School
Faculty
Mary Montgomery, MD Mary Montgomery, MD
Associate Physician
Division of Infectious Diseases
Brigham and Women's Hospital
Instructor of Medicine
Harvard Medical School
 

20
Supported by an independent educational grant from ViiV Healthcare. ViiV Healthcare was not involved in the development of content or selection of faculty for this educational activity.

Launch Date: April 26, 2022
Release Date: April 26, 2022
Expiration Date: March 31, 2023

March 31, 2023
Mini Module
7347
QuarterlyBrief2022_WebBanner(1150).gif
HIV